AC Immune SA (NASDAQ:ACIU): Are Analysts Optimistic? [Yahoo! Finance]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: Yahoo! Finance
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's loss has recently broadened since it announced a CHF54m loss in the full financial year, compared to the latest trailing-twelve-month loss of CHF55m, moving it further away from breakeven. As path to profitability is the topic on AC Immune's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate. View our latest analysis for AC Immune According to the 4 industry analysts covering AC Immune, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of CHF29m in 2025. Therefore, the company is expected to breakeven just over a year from no
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- Takeda Signs Option to Market Ascentage's Blood-Cancer Drug [BNN Bloomberg (Canada)]BNN Bloomberg
- Here's Why Shareholders May Want To Be Cautious With Increasing AC Immune SA's (NASDAQ:ACIU) CEO Pay Packet [Yahoo! Finance]Yahoo! Finance
- Blood Brain Barrier Market Untapped Growth Opportunities Analysis - Latest Report by InsightAce Analytic Pvt. Ltd. [Yahoo! Finance]Yahoo! Finance
- AC Immune SA (NASDAQ: ACIU) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.MarketBeat
- AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 [Yahoo! Finance]Yahoo! Finance
ACIU
Earnings
- 5/13/24 - Miss
ACIU
Sec Filings
- 6/20/24 - Form 6-K
- 5/21/24 - Form 6-K
- 5/16/24 - Form 144
- ACIU's page on the SEC website